The Effects of Chidamide Combined with Anti-myeloma Drugs on the Proliferation and Apoptosis of Myeloma Cells.
10.19746/j.cnki.issn.1009-2137.2021.04.026
- Author:
Yong LIU
1
;
Yun XU
1
;
Yan XIE
1
;
Guang-Hua CHEN
1
;
Wei LIU
2
;
Wei-Qin YAO
1
;
Shuang YAN
1
;
Ling-Zhi YAN
1
;
De-Pei WU
1
;
Cheng-Cheng FU
3
Author Information
1. Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Soochow National Clinical Research Center for Hematologic Diseases, Collaborative Innovation Center of Hematology, Ministry of Health Key Laboratory of Thrombosis and Hemostasis Suzhou 215000, Jiangsu Province, China.
2. Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China.
3. Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Soochow National Clinical Research Center for Hematologic Diseases, Collaborative Innovation Center of Hematology, Ministry of Health Key Laboratory of Thrombosis and Hemostasis Suzhou 215000, Jiangsu Province, China E-mail: fuchengchengsz@163.com.
- Publication Type:Journal Article
- MeSH:
Aminopyridines;
Apoptosis;
Benzamides;
Bortezomib/pharmacology*;
Cell Line, Tumor;
Cell Proliferation;
Humans;
Multiple Myeloma;
Pharmaceutical Preparations
- From:
Journal of Experimental Hematology
2021;29(4):1187-1194
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effects of chidamide combined with anti-myeloma drugs on the proliferation and apoptosis of myeloma cells.
METHODS:The proliferation inhibition of the cells was detected by CCK-8 method, and flow cytometry was used to detected the apoptosis of the cells.
RESULTS:Chidamide could inhibit the proliferation of myeloma cells and promote the apoptosis of primary myeloma plasma cells in a time- and dose-dependent manner (P<0.05). In NCI-H929 cell line, chidamide combined with low-dose bortezomib and lenalidomide showed synergistic effect, while combined with dexamethasone and pomalidomide showed additive effect. In MM.1s cell line, chidamide combined with bortezomib, dexamethasone, lenalidomide and pomalidomide all showed synergistic effects.
CONCLUSION:Chidamide inhibits proliferation of myeloma cells in a time- and dose-dependent manner and promotes apoptosis of primary myeloma plasma cells. Furthermore, it can enhance the inhibitory effect of anti-myeloma drugs.
